Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Operating Leases: 2019-2025

Historic Operating Leases for Northwest Biotherapeutics (NWBO) over the last 7 years, with Sep 2025 value amounting to $4.4 million.

  • Northwest Biotherapeutics' Operating Leases fell 7.89% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year decrease of 7.89%. This contributed to the annual value of $4.4 million for FY2024, which is 0.36% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Operating Leases is $4.4 million, which was down 3.83% from $4.6 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Operating Leases ranged from a high of $5.6 million in Q1 2021 and a low of $4.1 million during Q3 2022.
  • Over the past 3 years, Northwest Biotherapeutics' median Operating Leases value was $4.4 million (recorded in 2024), while the average stood at $4.4 million.
  • Its Operating Leases has fluctuated over the past 5 years, first rose by 23.12% in 2021, then declined by 21.91% in 2022.
  • Northwest Biotherapeutics' Operating Leases (Quarterly) stood at $5.2 million in 2021, then declined by 16.38% to $4.4 million in 2022, then increased by 1.92% to $4.5 million in 2023, then dropped by 0.36% to $4.4 million in 2024, then declined by 7.89% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $4.6 million for Q2 2025, and $4.5 million during Q1 2025.